Imetelstat + Best Available Therapy (BAT)
Phase 3Active 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis
Conditions
Myelofibrosis
Trial Timeline
Apr 12, 2021 → Jun 30, 2028
NCT ID
NCT04576156About Imetelstat + Best Available Therapy (BAT)
Imetelstat + Best Available Therapy (BAT) is a phase 3 stage product being developed by Geron for Myelofibrosis. The current trial status is active. This product is registered under clinical trial identifier NCT04576156. Target conditions include Myelofibrosis.
What happened to similar drugs?
2 of 18 similar drugs in Myelofibrosis were approved
Approved (2) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04576156 | Phase 3 | Active |
Competing Products
20 competing products in Myelofibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 36 |
| Nusivertib + Ruxolitinib + Momelotinib | Sumitomo Pharma | Phase 1/2 | 39 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 35 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Placebo for Navitoclax + Ruxolitinib + Navitoclax | AbbVie | Phase 3 | 40 |
| Mivebresib + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 21 |
| Navitoclax + Venetoclax | AbbVie | Pre-clinical | 26 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 44 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 27 |
| AZD1480 | AstraZeneca | Phase 1 | 29 |
| Bomedemstat | Merck | Phase 2 | 31 |
| Peginterferon alfa-2a | Merck | Phase 2 | 27 |
| Bomedemstat | Merck | Phase 1/2 | 32 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 21 |
| PIM447 + Ruxolitinib + LEE011 | Novartis | Phase 1 | 29 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 32 |
| Imatinib mesylate | Novartis | Phase 2 | 35 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 24 |
| Ruxolitinib + Ruxolitinib Placebo | Novartis | Phase 3 | 32 |
| Ruxolitinib | Novartis | Pre-clinical | 30 |